Ripple Therapeutics is a pharmaceutical/drug delivery company that originated from Interface Biologics, Inc. (IBI) following the divestiture of its surface modification business to Evonik (ETR:EFK). The leading product (IBE-814 IVT) is a fully degradable intravitreal dexamethasone prodrug implant designed for DME, RVO, and NIU indications. The target product profile aims for consistent drug release over 6-9 months using a 30G needle and 1/10th the loading of the primary commercial IVT product, suggesting potential reduction of steroid-related cataract and IOP adverse events. The company is also working on a distinct treatment for repeat expansion disorders such as Huntington's disease, myotonic dystrophy, and spinocerebellar ataxias by addressing the underlying cause of genetic dysfunction that leads to disease onset and progression. Ripple Therapeutics has assembled a team with extensive experience in drug discovery, genetics, clinical research, and operations, and is supported by a prominent group of investors dedicated to improving the lives of patients and families affected by repeat expansion disorders.
Ripple Therapeutics
Headquarters
Canada